State-of-art nano-biotechnology revolutionized healthcare management via developing smart rapid diagnostics systems and nanomedicine along with efficient drug delivery systems designed for targeted diseases.  It has been investigated that a standard technology is useful but sometimes is not applicable to everyone due to variabilities in human genomics. Thus, investigating efficient nano-systems (mainly biosensor for efficient diagnostics and nanomedicine for treatment of higher efficacy) of tunable performance is essential to design and develop nano-enabled high-performance systems for intelligent health management; toward point-of-care as well.

In this direction, I am exploring magneto-electric nanoparticles (MENPS, size 25 ± 5 nm) for magnetically guided delivery to the brain and on-demand release of a bound drug on applying ac-magnetic field stimulation to manage CNS diseases. It has been investigated that the MENPs cross the BBB without affecting cell integrity, distributed uniformly in all brain cell types, releases CRISPR-Cas9 on ac-magnetic stimulation, without affecting motor coordination function of animal, and without causing tissue as well as blood toxicity. To develop efficient diseases management, I developed miniaturized nano-enabled biosensing systems to detect SARS-CV-2 for the efficient diagnostics of COVID-19 infection timely using an immunosensor technique. Such nano-supported technologies have significance to develop novel future technology for therapy development, early-stage diseases diagnostics, and therapy monitoring to manage health in personalized manner. As recent effects, we are engaged in introducing aspects of artificial intelligence (AI) and internet of medical things (IoMT) to make our developed nano-therapeutics and diagnostics systems more efficient, effective, and affordable.